mRNA vaccines have provided one good answer to humankind’s latest grand challenge, but the technology has yet to mature. If the success story of these nucleotide-based drugs is to continue, manufacturers must look to ease the headaches associated with their manufacture.
1
min read
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.